Ultimovacs touts positive early clinical results for universal cancer vaccine

By The Science Advisory Board staff writers

October 19, 2020 -- Ultimovacs reported five-year overall survival data from its phase I clinical trial evaluating UV1, a universal cancer vaccine candidate, in patients with non-small cell lung cancer.

UV1 is a peptide-based vaccine which induces specific T-cell responses against the universal cancer antigen, telomerase. The product has been developed as a cancer vaccine and can be used in combination with other immunotherapies that require ongoing T-cell responses for their mode of action.

The phase I clinical trial included a total of 18 non-small cell lung cancer patients whose disease has not processed after receiving at least a second line treatment with chemotherapy. These patients received UV1 monotherapy as a maintenance treatment. In the trial, each patient reached at least 60 months of follow-up treatment with UV1. After five years, the overall survival rate was 33% and the median progression free survival rate was 10.7 months.

UV1 is also being evaluated in three phase II combination clinical trials. Ultimovacs anticipates announcing data from these studies in 2022.

Lineage Cell, Cancer Research U.K. advance cancer vaccine
Lineage Cell Therapeutics and partner Cancer Research U.K. have posted positive preliminary phase I results from an ongoing study of VAC2 in non-small...
RNAimmune gets $2.35M for mRNA therapeutics, vaccines
RNAimmune has secured $2.35 million in seed round financing from multiple venture capital firms to advance its COVID-19 vaccine RV1730 program and...
Vaccibody, Nektar begin customized cancer vaccine trial
Vaccibody and Nektar Therapeutics have started a phase I/IIA trial for a personalized cancer DNA vaccine for patients with advanced squamous cell carcinoma...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter